Table 2.
Characteristics of Individuals on Combination Antiretroviral Therapy, North American AIDS Cohort Collaboration on Research and Design, 2000–2005
| Characteristic | 2000 |
2005 |
||||||||||
| Viral Load >1,000 copies/mL (n = 1,480) |
Viral Load <1,000 copies/mL (n = 3,524) |
Viral Load >1,000 copies/mL (n = 778) |
Viral Load <1,000 copies/mL (n = 3,875) |
|||||||||
| With a Genotypic Test Within Year (n = 817) |
No Genotypic Test Within Year (n = 663) |
With a Genotypic Test Within Year (n = 486) |
No Genotypic Test Within Year (n = 292) |
|||||||||
| % | Median (IQR) | % | Median (IQR) | % | Median (IQR) | % | Median (IQR) | % | Median (IQR) | % | Median (IQR) | |
| Male sex | 80 | 81 | 82 | 74 | 79 | 80 | ||||||
| White | 43 | 42 | 54 | 34 | 34 | 42 | ||||||
| Use of nucleoside-analogue reverse transcriptase inhibitors prior to start of antiretroviral therapy | 57a | 69a | 44 | 46 | 39 | 28 | ||||||
| Lapse in antiretroviral therapy during the year | 25a | 33a | 16 | 26a | 50a | 25 | ||||||
| Injected drug use | 23 | 22 | 20 | 19 | 22 | 19 | ||||||
| Age, years | 40 (36–47) | 40 (36–46) | 41 (36–47) | 43 (37–49) | 45 (39–51) | 44 (39–51) | ||||||
| CD4+, cells/mm3 | 229 (90–380) | 221 (83–400) | 430 (269–635) | 229 (100–418) | 224 (103–380) | 440 (300–628) | ||||||
| Viral load, copies/mL | 13,991a (2,588–72,849) | 17,000a (3,854–72,756) | <50 | 8,770a (1,160–52,200) | 24,456a (5,575–100,010) | <50 | ||||||
Abbreviation: IQR, interquartile range.
a
P < 0.05 by χ2 test or Wilcoxon rank sum test comparing those with and without genotype tests among those at risk for testing (viral load >1,000 copies/mL).